君实生物,2025没有退路

健识局
Yesterday

PCSK9抑制剂算是医保谈判的常客,这几年经常参与国谈,至今有三款药谈判成功,而且医保降价幅度都很大。去年,信达的托莱西单抗谈判成功,价格从一针1388元降到不超300元。唯一硬抗的是诺华的英克司兰钠,那当然没有谈成,依旧卖9988元一针。到了今年,市场格局就发生了变化。国内企业对降血脂这一慢病领域十分热衷,没有赶上去年谈判的康方生物、君实生物、恒瑞产品在过去大半年里密集获批相关产品。今年,“进...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10